RxDoctor Payments Data

Dhiekson Silva, MD

Family Medicine · Houston, TXNPI 1760748388

Payments from drug & device makers

$1,609in general payments, 2019–2025

Across 79 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$642
  • Abbott$353
  • Lilly USA, LLC$224
  • AstraZeneca$106
  • Amarin Pharma, Inc.$69
  • Astellas Pharma US Inc$41
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$1,609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,609 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,649
Medicare patients
89
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$214,687
OzempicSemaglutide87$116,440
TrulicityDulaglutide49$87,762
JanuviaSitagliptin Phosphate38$56,534
EliquisApixaban33$34,291
FarxigaDapagliflozin Propanediol25$29,294
VascepaIcosapent Ethyl58$28,789
LinzessLinaclotide29$23,571
TradjentaLinagliptin15$21,903
Janumet XrSitagliptin Phos/Metformin Hcl13$20,076
Synjardy XrEmpagliflozin/Metformin Hcl12$19,871
XareltoRivaroxaban12$17,501
MyrbetriqMirabegron25$16,881
EntrestoSacubitril/Valsartan18$16,435
JanumetSitagliptin Phos/Metformin Hcl14$16,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$31$256,461160 claims
Novo NordiskOzempic$642$116,44087 claims
Lilly USA, LLCTrulicity$224$87,76249 claims
AstraZenecaFarxiga, Symbicort$106$34,81536 claims
PfizerEliquis$31$34,29133 claims
Astellas Pharma US IncMyrbetriq$41$16,88125 claims
NovartisEntresto$18$16,43518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →